MedTrace Logo

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

NCT04906473 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2021-05-28

No results posted yet for this study

Summary

to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001 in patients with advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

KY100001

KY100001; Tablet; Oral route; Dose escalation and dose extension

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Lin Shen, prof. · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-12-31
Completion
2023-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906473 on ClinicalTrials.gov